BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05905783 (Izokibep in Hidradenitis Suppurativa): BVCT ex-ante prediction vs. reported outcome

On 22 Jul 2023, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 12 Aug 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially fairly sufficient (superior to adalimumab and non-inferior to sonelokimab).

Clinical Trial

NCTID
NCT05905783
Drug Name
Izokibep
Drug MoA
IL-17A Inhibitor
Drug Modality
small protein scaffold-based biologic
Drug Class
Best-In-Class
Therapeutic Area
Immune System Diseases
Indication
Hidradenitis Suppurativa
Human Patients
258
Sponsor
Acelyrin
Phase
Phase 3

Prediction of , index 1188

Prospective Prediction
Prediction Index
1188
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit superior to adalimumab and non-inferior to sonelokimab)
Technical Prediction
SUCCESS (statistically significant)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
387 days in advance
Readout Data Interpretation
izokibep achieved 14% placebo-adjusted HiSCR100; superior to single-digit placebo-adjusted HiSCR100 achieved by adalimumab; and above the inferior threshold compared with 20%-30% placebo-adjusted HiSCR100 achieved by sonelokimab.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially fairly sufficient (superior to adalimumab and non-inferior to sonelokimab)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa
Phase
Phase 3
Status
Terminated
Enrollment
258
Lead sponsor
ACELYRIN Inc.
Conditions
Hidradenitis Suppurativa
Interventions
DRUG: Placebo; DRUG: Izokibep
Design
Randomized · Parallel · Double
Primary purpose
Treatment
Start
2023-06-22
Primary completion
2024-07-24
Completion
2025-01-27
Results first posted
2025-10-15
Primary outcomes
  • Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 12 (Week 12)

NCT05905783 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials